Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265850 · ClinicalTrials.gov registry record · Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,334
- Enrollment target
NCT00265850 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 2,334 participants.
The verdict
NCT00265850, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,334 participants
- Enrollment target
Study Summary
PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer. RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as fluorouracil, leucovorin, oxaliplatin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibodies together with combination chemotherapy may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with cetuximab and/or bevacizumab in treating patients with colorectal cancer.
Interventions
- DRUG FOLFIRI
- BIOLOGICAL cetuximab
- BIOLOGICAL bevacizumab
- DRUG FOLFOX or
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,334 participants |
| Start Date | 2005-11 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265850
The ClinicalTrials.gov registry entry for NCT00265850 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which FOLFIRI is the first listed.
NCT00265850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265850 about?
NCT00265850 is a clinical study titled "Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer". PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer. RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tu...
What is the current status of trial NCT00265850?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,334 participants. The study started on 2005-11. Estimated completion is 2018-01.
What interventions are being tested in trial NCT00265850?
The interventions under investigation include: FOLFIRI (DRUG), cetuximab (BIOLOGICAL), bevacizumab (BIOLOGICAL), FOLFOX or (DRUG).
Who is sponsoring clinical trial NCT00265850?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.